help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hadsell, D. L.
Right arrow Articles by Lee, A. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hadsell, D. L.
Right arrow Articles by Lee, A. V.
Endocrinology Vol. 142, No. 4 1479-1488
Copyright © 2001 by The Endocrine Society


ARTICLES

Inability of Overexpressed des(1–3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules1

Darryl L. Hadsell, Tatiana Alexeenko, Yann Klemintidis, Daniel Torres and Adrian V. Lee2

Department of Pediatrics, U.S. Department of Agriculture/Agricultural Research Service Children’s Nutrition Research Center (D.L.H., T.A., Y.K., D.T.); and Breast Center, Department of Medicine (A.V.L.), and Department of Molecular and Cellular Biology (D.L.H., A.V.L.), Baylor College of Medicine, Houston, Texas 77030

Address all correspondence and requests for reprints to: Dr. Darryl L. Hadsell, Department of Pediatrics, U.S. Department of Agriculture (USDA)/Agrucultural Research Service (ARS) Children’s Nutrition Research Center, Houston, Texas 77030. E-mail: dhadsell{at}bcm.tmc.edu


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Overexpression of des(1–3) human insulin-like growth factor I (IGF-I) in the mammary glands of transgenic mice (WAP-DES) inhibits apoptosis during natural, but not forced, mammary involution. We hypothesized that this differential response would correlate with the expression of IGF signal transducers. Forced and natural involution were analyzed in nontransgenic and WAP-DES mice beginning on day 16 postpartum. During natural involution, mammary gland wet weight was higher and apoptosis was lower in WAP-DES than in nontransgenic mice. The WAP-DES transgene had no effect on these parameters during forced involution. Mammary tissue concentrations of the transgene protein were 2- to 10-fold higher than those of endogenous IGF-I. Western blot analysis of pooled mammary tissue extracts demonstrated only slightly higher phosphorylation of the IGF signal transducers insulin receptor substrate-1 (IRS-1) and Akt in the WAP-DES than in nontransgenic mice. Dramatic early reductions in phospho-IRS-1, phospho-Akt, IRS-1, IRS-2, and Akt proteins occurred during forced, but not natural, involution. The abundance of the IGF-I receptor and the messenger RNAs for the IGF-I receptors, IRS-1 and -2, were not affected by either genotype or involution. These findings support the conclusions that mammary cells lose their responsiveness to insulin-like signals during forced involution, and that posttranscriptional or posttranslational regulation of IRS-1 and IRS-2 may play a role in this loss.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
IN MICE, MAMMARY gland involution begins to occur naturally between days 16 and 19 of lactation (1). This occurs through increased mammary cell apoptosis, which is induced in response to decreased removal of milk by the suckling pups. This process has been extensively studied using an experimental paradigm described as forced involution (2). In this paradigm, mammary involution is intentionally induced by removal of the suckling pups at peak lactation. Forced mammary gland involution occurs in two distinct stages (3). During stage 1, engorgement of the gland with milk is associated with increased epithelial apoptosis and decreased expression of milk protein genes. This stage is also characterized by dramatic increases in the expression of Bcl-2 homology proteins (4), transcription factors (2), and cell cycle regulators (5). The second stage of forced involution is characterized by increased expression and activity of proteases and intensive tissue remodeling (3). These dramatic changes in gene expression and cellular apoptosis are believed to result from the loss of local trophic factors in response to milk stasis (1). These factors include PRL, glucocorticoids, and insulin-like growth factor I (IGF-I) (6, 7, 8). For IGF-I, this loss is hypothesized to be a consequence of increased expression of IGF-binding proteins that bind IGF-I and reduce bioavailability (8, 9, 10). However, in addition to the loss of extracellular trophic signals, decreased cellular responsiveness to these signals may be a mechanism for induction of apoptosis during mammary gland involution. Studies in cell culture models suggest that the abundance and/or activation of the intracellular IGF/insulin signal transducer insulin receptor substrate-1 (IRS-1) determines the ability of IGF-I and/or insulin to protect cells from apoptosis (11, 12). This protective effect is known to occur through activation of PI3-kinase and Akt, followed by phosphorylation-dependent inactivation of the proapoptotic BH protein, Bcl-associated death promoter (BAD) (13).

Overexpression of wild-type IGF-I in the mammary glands of transgenic mice has been demonstrated to inhibit apoptosis when analyzed on day 5 of forced involution (14). Studies in our own laboratory have shown that overexpression of the des(1, 2, 3) truncated form of IGF-I under control of the promoter from the rat whey acidic protein gene (WAP-DES) inhibits the apoptosis that occurs during natural mammary involution and increases the frequency of spontaneous mammary tumors (15, 16). However, preliminary studies in our laboratory suggested that WAP-DES was incapable of inhibiting apoptosis during forced involution. The goals of the current study were, therefore, 1) to characterize in greater detail the ability of overexpressed des(1–3])human (h) IGF-I to inhibit apoptosis during forced vs. natural mammary gland involution, and 2) to determine whether expression of IGF signal transducers could account for differential responsiveness of the involuting mammary gland to overexpressed des(1, 2, 3)hIGF-I.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Animals
The transgenic mice used in these studies were FVB mice carrying the previously described WAP-DES transgene (15). These animal studies were conducted using procedures outlined in the NIH Guide to Care and Use of Experimental Animals and were approved by the Baylor College of Medicine animal care and use committee. Nontransgenic (n = 36) and WAP-DES (n = 39) mice were allowed to complete a normal pregnancy. For the purposes of this study, the day of parturition is referred to as day 0. On day 2 postpartum, the litter size of each dam was adjusted to 10 by cross-fostering. Natural involution was studied in mammary tissue samples collected on days 16, 18, 20, and 22 postpartum. Forced involution was induced by removal of the pups on day 16 and studying tissue samples collected on days 17–20 postpartum. Mammary glands were collected from each mouse and either snap-frozen in liquid nitrogen or fixed in 10% neutral buffered formalin and processed for immunohistochemistry. Mammary gland wet weight was estimated from one of the number four mammary glands.

Histology
Tissue was fixed and processed for immunohistochemistry (15). Mammary tissue sections were stained for apoptosis using a previously described (17) modification of the terminal deoxynucleotidyltransferase-mediated deoxy-UTP nick end labeling (TUNEL) technique (18). Labeling indexes were obtained by counting labeled and unlabeled epithelial cells in 8–12 (~1000 cells total) fields at x1000 magnification. Immunohistochemistry for IRS-1 was conducted on paraffin-embedded sections of mammary tissue using a rabbit antihuman IRS-1 antibody (Upstate Biotechnology, Inc., Lake Placid, NY). All incubations were performed at room temperature, and all washing was performed with 0.15 M NaCl, 0.01 M Tris-HCl (pH 7.4), and 0.05% Tween 20 unless otherwise stated. Slides were cut at 3–4 µm, baked overnight at 58 C, and deparaffinized using a Shandon-Lipshaw Varistain (program 2) (Shandon Inc., Pittsburgh, PA). Heat-induced antigen retrieval was performed in 0.1 M Tris-HCl (pH 9.0) for 5 min. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide solution for 5 min. Avidin/biotin blocking was performed with the A/B blocking kit (Vector Laboratories, Inc., Burlingame, CA) by incubation in solution A for 15 min and then in solution B for 15 min. Slides were then incubated in IRS-1 antibody (1:800 dilution in TBS plus 1% BSA) for 1 h, biotin-labeled secondary antibody (1:200) for 30 min, and horseradish peroxidase-labeled avidin (1:200) for 30 min. For a negative control, slides were incubated with purified rabbit Ig (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Detection was then performed by incubation with diaminobenzidine (DAKO Corp., Carpinteria, CA) for 15 min, followed by enhancement with 0.2% osmium tetroxide for 30 sec. Slides were counterstained with 0.05% methylene green for 30 sec, dehydrated, and mounted using cytoseal. For detection of steroid hormone receptors we used the same method with antibodies to estrogen receptor {alpha} (6F11, Vector Laboratories, Inc.) and progesterone receptor (1294, DAKO Corp.).

RNA analysis
Total RNA was isolated from about 100 mg tissue using Ultraspec (Biotecx, Houston, TX) as described by the manufacturer. Ribonuclease protection assays (RPA) were used to analyze the abundance of the messenger RNAs (mRNAs) for IGF-I receptor (IGF-IR), IRS-1, and IRS-2. The RPA probe for murine IGF-IR has been previously described (16). The probes for murine IRS-1 and -2 were produced by cloning PCR fragments amplified from mouse genomic DNA. For the murine IRS-1 probe, pDT1-mIRS-1, a 447-bp PCR product, was amplified with the forward and reverse primers, 5'-CAT CCG AAT TCA CCT GCG CAA GCC CAA GAG T-3' and 5'-AAA GAG GAT CCT GCC AGA CCT CCT TGA ACG C-3', respectively. For the murine IRS-2 probe, pDT1-mIRS-2, a 329-bp PCR product, was amplified with the forward and reverse primers, 5'-GGT AAG AAT TCA GGA CCT TCC CAG TAA ACG G-3' and 5'-AAT AAG GAT CCT GGT CAT TGT CTC CGC TGC A-3', respectively. The temperature-time settings for these 30 cycle amplifications were 95 C for 1 min, 65 C for 2 min, and 72 C for 3 min. The resulting products were digested with EcoRI and BamHI and then ligated into the corresponding sites in pBluescript (Stratagene, La Jolla, CA). The pTRI-cyclophilin-mouse antisense control template (Ambion, Inc., Austin, TX) was used to measure cyclophilin mRNA as a loading control. Antisense complementary RNAs were produced using T3 RNA polymerase and resulted in probes of 502, 384, and 138 nucleotides (nt) for IRS-1 IRS-2, and cyclophilin, respectively. RPAs were conducted using the RPA III kit (Ambion, Inc.). Quantitative data were obtained using the Storm PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA.)

IGF-I measurement
Acetic acid extracts (19) of mammary tissue were assayed for both human IGF-I and mouse IGF-I using species-specific assay kits (Diagnostics Systems Laboratories, Inc., Webster, TX). For the human IGF-I assay, approximately 50 mg frozen mammary tissue were removed from liquid nitrogen and immediately homogenized in 2 ml ice-cold 1 M acetic acid. Tissue extracts prepared from this homogenate were neutralized by diluting 1:6 in a neutralization buffer provided with the assay kit and then diluted in the assay zero standard. This assay had a working range of 0.15–20 ng/ml and a minimum detection limit of 36 ng/g tissue. The intraassay coefficient of variation was 6%. The specificity of the assay for the human IGF-I transgene product was evident by the fact that parallel analysis of mammary tissue extracts prepared from nontransgenic mice failed to give a signal above the zero assay standard (data not shown). For analysis of mouse IGF-I, mammary tissue was homogenized in 5 vol 1 M acetic acid. Extracts were than neutralized as described above. The rodent-specific RIA had a working range of 5.3–133 ng/ml and a minimum sensitivity of 114 ng/g tissue. The intraassay coefficient of variation was 4%.

Western blotting
Mammary tissue extracts were prepared for protein analysis as previously described (20). For each genotype time point, equivalent amounts of protein from four individual mammary gland extracts were pooled. Immunoprecipitations for IRS-1 and IRS-2 were conducted using 5 µg of each antibody (Upstate Biotechnology, Inc., Lake Placid, NY) and 500 µg of protein from each pool as previously described (20). These immunoprecipitates were then resolved by 8% SDS-PAGE and blotted to nitrocellulose (Schleicher & Schuell, Inc., Keene, NH). The resulting blots were analyzed for phosphotyrosine as previously described (20). Equal protein concentrations of the pooled extracts (10–100 µg depending upon the antigen to be detected) were also directly electrophoresed on 8% SDS-PAGE gels and used for Western blot analysis. Equal protein loading was assessed after electrophoretic transfer by staining the membrane in 0.1% Ponceau S in 5% acetic acid (Sigma, St. Louis, MO) for 5 min. Blots generated with these extracts were probed with antibodies specific to IGF-IR (1:1000; {alpha}-IR3, Calbiochem, San Diego, CA), IRS-1 (1:1000; Upstate Biotechnology, Inc.), IRS-2 (1:1000; Upstate Biotechnology, Inc.), p85 subunit of phosphatidylinositol-3 kinase (1:2000; Upstate Biotechnology, Inc.), phospho-Akt (1:1000; New England Biolabs, Inc., Beverly, MA), total Akt (1:1000; New England Biolabs, Inc.), phospho-BAD (1:1000; Upstate Biotechnology, Inc.), and total BAD (1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) using previously described procedures (20). The blots were also probed with an antibody to keratin 18 (K18, Progen Biotechnik, Heidelberg, Germany) to examine epithelial content. Autoradiograms were generated by exposing the blots for varying times from 10 sec to 30 min. The resulting autoradiograms were scanned on the Personal Densitometer SI (Molecular Dynamics, Inc., Sunnyvale, CA) to provide quantitative data. For Quantitative comparison of IRS and Akt, exposure times were chosen that allowed for the detection of signals with the least abundance. The data were expressed as the integrated area under the curve, assuming equivalent loading based Ponceau S staining and the bicinchoninic acid protein assay (20).

Statistics
Quantitative data on mammary tissue weight, apoptosis, and hIGF-I concentration were analyzed using the general linear models procedure in SPSS for Windows version 10.0.0 (SPSS, Inc., Chicago, IL). The effects of involution and genotype on K18, phospho-Akt and total Akt were determined by one-way ANOVA on data collapsed for day within each genotype/involution combination. This was done because there was no apparent effect of day of Akt phosphorylation and abundance. Decreased apoptosis or increased mammary gland weight in the WAP-DES mice on individual days was tested for using a one-way unpaired t test. Differences were considered significant at P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Preliminary analysis of the WAP-DES transgenic mice has demonstrated that overexpressed des(1, 2, 3)IGF-I can inhibit apoptosis during natural, but not forced, mammary gland involution. To analyze in detail this differential effect, cohorts of nontransgenic or WAP-DES mice were sampled on several days during either natural or forced mammary involution. During the 6 days that natural involution was studied, mammary gland wet weight declined in the nontransgenic mice by 53%, indicating that tissue loss and/or decreased milk synthesis were occurring (Fig. 1AGo). In contrast, the decline in mammary gland weight in the WAP-DES mice was delayed by 2 days, and hence, tissue weight was maintained at 29–30% greater than that of nontransgenic mice (P < 0.05). Analysis of mammary tissue apoptosis during natural involution (Fig. 1BGo) revealed only 0.2–0.3% apoptosis in nontransgenic and WAP-DES mice on day 16 postpartum. By day 20 postpartum, this value increased 14-fold to 2.8 ± 0.6% in the nontransgenic mice. In contrast, mammary tissue apoptosis in the WAP-DES mice on day 20 postpartum, although increased to 1.4 ± 0.3%, was only 51% of that observed in the nontransgenic animals (P < 0.05). By day 22 postpartum, mammary tissue apoptosis in the WAP-DES mice was still only 61% of that observed in the nontransgenic mice (P < 0.05). Thus, des(1, 2, 3)hIGF-I overexpression inhibited apoptosis during natural involution of the mammary gland.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 1. Analysis of mammary gland weight (A and C) and apoptosis (B and D) during either natural (A and B) or forced (C and D) involution. Lactating nontransgenic (•) or WAP-DES ({circ}) mice were placed with litters of 10 pups each at 2 days postpartum. At days 16, 18, 20, and 22 postpartum, mammary glands were collected for analysis of natural involution. Forced involution was induced at day 16 postpartum. Mammary tissue samples were then collected at days 17, 18, 19, and 20 postpartum. Wet weight was measured on one of the number 4 mammary glands. Apoptosis was detected by TUNEL staining and was enumerated by counting positive and negative cells in 10 randomly chosen x100 fields. *, P < 0.05.

 
During forced involution, mammary gland wet weight in nontransgenic and WAP-DES mice displayed similar changes (Fig. 1CGo), with an initial, transient increase due to milk accumulation followed by weight loss toward the end of the 4-day time period. Mammary cell apoptosis also underwent similar changes between nontransgenic and WAP-DES mice during forced involution (Fig. 1DGo), supporting the conclusion that overexpression of des(1, 2, 3)hIGF-I does not inhibit the apoptosis that occurs during the first 4 days of forced involution.

A decreased transgene expression and lower abundance of the transgene protein during forced involution would explain the inability of WAP-DES to protect mammary cells from apoptosis. To test this hypothesis, species-specific assays were used to measure both human and mouse IGF-I in mammary tissue extracts from WAP-DES and nontransgenic mice during natural and forced mammary involution (Fig. 2Go). At 16 days postpartum, the concentration of des(1, 2, 3)hIGF-I in mammary tissue from the WAP-DES mice averaged 1090 ± 1038 ng/g tissue (Fig. 2AGo). During natural involution, these concentrations gradually increased to a maximum of 4012 ± 233 ng/g tissue on day 22. In contrast, the concentration of endogenous IGF-I was below the detection limit of 114 ng/g tissue for both nontransgenic and WAP-DES mice throughout the course of natural involution. The concentration of des(1, 2, 3)hIGF-I in the mammary tissue of WAP-DES mice during forced involution ranged from a high of 1599 ± 410 ng/g tissue on day 17 to 969 ± 292 ng/g tissue on day 20 postpartum (Fig. 2BGo). During forced involution, concentrations of endogenous IGF-I ranged from below the limit of detection on day 17 to as much as 402 ± 37 ng/g tissue on day 18 postpartum. The concentration of endogenous IGF-I during forced involution was also slightly, but significantly (P < 0.05), lower in mammary tissue from WAP-DES compared with nontransgenic mice. No significant differences were observed in des(1, 2, 3)hIGF-I concentrations among the first three time points of natural involution (days 16, 18, and 20) and forced involution (days 17 18, and 19). This is the time when significant differences were observed in apoptosis and wet weight between nontransgenic and WAP-DES mice (see Fig. 1Go) during natural, but not forced, involution.



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. Analysis of IGF-I protein in mammary tissue extracts prepared from mice during either natural or forced involution. Tissue concentrations of endogenous IGF-I were measured by species- specific RIA in mammary tissue extracts from either nontransgenic () or WAP-DES () mice during either natural (A) or forced (B) involution. The tissue concentration of des(1 2 3 )hIGF-I ({square}) was measured using a species-specific immunoradiometric assay on mammary tissue extracts from WAP-DES mice during natural (A) or forced (B) involution. Each bar represents the mean ± SEM for three or four mice. The dashed line indicates the detection limit for the measurement of endogenous IGF-I. Arrows show the day of peak apoptosis. The asterisk in A indicates a statistically significant increase in des(1 2 3 )hIGF-I on day 22 postpartum compared with all other time points. Asterisks in B indicate statistically significant differences (P < 0.05) between nontransgenic and WAP-DES mammary tissue for endogenous IGF-I.

 
To determine whether the apparent lack of responsiveness to WAP-DES was due to loss of IGF-IR expression, the abundance of both IGF-IR protein and mRNA was examined. Western blot analysis for IGF-IR ß-subunit detected the 97-kDa subunit at variable levels in the pooled extracts from both nontransgenic and WAP-DES mammary glands (Fig. 3AGo). The receptor protein, however, was not diminished by forced mammary involution. The variation observed in the abundance of the receptor also showed little apparent relationship to genotype. Western blotting for K18 demonstrated variation unrelated to genotype or involution. This was repeatedly found with all of the blots in which K18 was measured (see also Figs. 4Go and 7Go). Furthermore, statistical analysis of the densitometry data from all three K18 blots failed to detect a significant change in response to either genotype or involution (data not shown). Ribonuclease protection analysis demonstrated that the abundance of the IGF-IR mRNA was not diminished by forced involution and was little affected by the WAP-DES transgene (Fig. 3BGo).



View larger version (89K):
[in this window]
[in a new window]
 
Figure 3. Expression of the IGF-IR during mammary gland involution. Western blot analysis of IGF-IR (A) abundance in mammary tissue extracts prepared from either nontransgenic (lanes 3–7 and 13–16) or WAP-DES (lanes 8–12 and 17–20) mice during either natural (lanes 3–12) or forced (lanes 13–20) involution. Each lane contains equal amounts of protein (100 µg/lane) from a pooled extract representing four individual mice. Protein extracts from MCF-7 cells cultured in the absence or presence of IGF-I (40 ng/ml) for 15 min serve as positive controls and are in lanes 1 and 2, respectively. The blots were also probed for K18 to determine epithelial content. No signal was observed for K18 in lanes 19 and 20 due to a localized transfer problem. The results of ribonuclease protection analysis of the IGF-IR mRNA (B) in total RNA prepared from mammary tissue of either nontransgenic (lanes 1–4 and 9–12) or WAP-DES (lanes 5–8 and 13–16) mice during either natural (lanes 1–8) or forced (lanes 9–16) are shown. Each lane contains 20 µg RNA from a pooled RNA sample representing a minimum of four mice. Total RNA prepared from kidney served as a positive control (lane 17). Yeast RNA served as a negative control (lane 18). The undigested probe is in lane 19. The sizes of the undigested probe fragments was 362 and 168 nt for the IGF-IR and cyclophilin probes, respectively. On digestion of the RPA reactions with ribonuclease, protected fragments of 302 and 103 nt were generated for IGF-IR and cyclophilin mRNAs, respectively.

 


View larger version (65K):
[in this window]
[in a new window]
 
Figure 4. Phosphorylation and abundance of IGF-IR signaling proteins in mammary tissue during involution. Tyrosine phosphorylation of IRS-1 and -2 (A) was determined in pooled mammary tissue extracts. Immunoprecipitation was conducted with 500 µg protein using antibodies specific for IRS-1 or -2. Phosphotyrosine was detected in these immunoprecipitates by Western blotting with the antiphosphotyrosine antibody (RC20). Western blotting was conducted using equal amounts (30 µg/lane) of protein from pooled mammary tissue extracts prepared from either nontransgenic (lanes 3–8 and 15–18) or WAP-DES (lanes 9–12 and 19–22) mice during either forced or natural mammary gland involution. The resulting blots were probed with antibodies specific for IRS-1, IRS-2, P85, or K18 (A). Extracts from MCF-7 cells treated for 15 min in either the absence (lanes 1 and 13) or presence (lanes 2 and 14) of 40 ng/ml IGF-I served as positive controls. Densitometric analysis of IRS-1 () and IRS-2 ({blacksquare}) in mammary tissue extracts during either natural (B) or forced (C) mammary involution. Because the effect of genotype was small, the data were pooled across genotype. Each bar represents the mean ± SD for the two observations. Arrows indicate the day of peak apoptosis.

 


View larger version (47K):
[in this window]
[in a new window]
 
Figure 7. Phosphorylation and abundance of Akt in mammary tissue during involution. Phosphorylation of Ser163 on Akt was detected using an antiphospho-Akt antibody (A). The blot was then reprobed with antibodies against total Akt and K18. Pooled extracts were prepared from nontransgenic (lanes 3–7 and 12–15) or WAP-DES (lanes 8–11 and 16–19) mice during either natural (lanes 3–11) or forced (lanes 12–19) involution. Each lane was loaded with 100 µg protein. Extracts from MCF-7 cells treated for 15 min in either the absence (lane 1) or presence (lane 2) of 40 ng/ml IGF-I served as positive controls. Densitometric analysis was used to compare phosphorylated-Akt (B) and total Akt (C) in mammary tissue extracts prepared from either nontransgenic ({blacksquare}) or WAP-DES () mice during either natural or forced mammary involution. The data are expressed as the area under the curve (A.U.C.). Because the effect of day was small, the data were pooled within each genotype/involution combination. Each bar represents the mean ± SD for the four or five pools in each group. Bars with different superscripts differ significantly (P < 0.05).

 
To determine whether the inability of overexpressed IGF-I to inhibit apoptosis was associated with diminished IGF-IR signaling capacity, phosphorylation of IRS-1 and -2 was examined (Fig. 4Go). Western blot analysis of immunoprecipitates prepared from pooled mammary tissue extracts demonstrated abundant tyrosine phosphorylation of IRS-1 (Py-IRS-1) during natural involution (Fig. 4AGo, lanes 3–12). The degree of IRS-1 phosphorylation appeared to be slightly higher in pooled extracts from the WAP-DES mice on days 20 and 22 than in the nontransgenic (compare lanes 6 and 7 with 11 and 12 in Fig. 4AGo). This effect, however, was not dramatic. During forced involution, phosphorylation of IRS-1 was detected only in the day 17 nontransgenic pool (Fig. 4AGo, lane 15). Phosphorylation of IRS-2 (Py-IRS-2) was not detected during natural involution, but was present at detectable, but low, levels in some of the pools obtained from mammary tissue during forced involution (Fig. 4AGo, lanes 15–22). Western blot analysis demonstrated abundant IRS-1 and -2 protein during natural involution in mammary gland extracts from both nontransgenic (Fig. 4AGo, lanes 3–7) and WAP-DES (Fig. 4AGo, lanes 8–12) mice. The abundance of these two proteins was similar between nontransgenic and WAP-DES mice on days 8–18 postpartum. Both IRS-1 and -2 decreased on days 20 and 22 postpartum (Fig. 4AGo, lanes 6, 7, 11, and 12). For IRS-1, this decrease was slightly greater for the nontransgenic mice than for the WAP-DES mice. For IRS-2, the decrease appeared to be delayed 1 day in WAP-DES compared with nontransgenic mice. For both proteins, however, the apparent effect of the transgene was relatively small compared with the effect of forced involution. Consequently, the densitometric data from the IRS-1 and -2 blot were pooled across genotype, as presented in Fig. 4Go, B and C.

Abundance of IRS-1 and -2 decreased over the course of natural involution by 70% and 93%, respectively (Fig. 4BGo). For IRS-1, the decrease occurred gradually throughout the course of natural involution. For IRS-2, the decrease was only apparent on days 20 and 22 when apoptosis was increased. During forced mammary involution, a dramatic reduction in IRS-1 and -2 protein abundance preceded the onset of apoptosis in both the nontransgenic and WAP-DES mice (Fig. 4AGo, lanes 15–22). On day 17 postpartum, after only 24 h of forced involution, mammary gland IRS-1 and -2 abundance was reduced by 54% and 96% compared with that on day 16 of lactation (Fig. 4Go, B and C). By day 18 postpartum, IRS-1 was reduced by 97%, and IRS-2 was undetectable. Reprobing the same blots with antibodies to the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3 kinase) and K18 demonstrated little effect of genotype or mammary gland involution (Fig. 4AGo) on the abundance of these two proteins. The decrease in IRS-1 protein abundance during forced involution was confirmed by immunohistochemical staining of mammary tissue sections (Fig. 5Go). Intense cytoplasmic IRS-1 staining was observed in the mammary epithelial cells of nontransgenic mice undergoing natural involution (Fig. 5AGo). In the absence of primary antibody, only a low level of background staining was detected (Fig. 5Go, B and D). In mammary epithelial cells of mice undergoing forced involution, the intensity of IRS-1 staining was reduced to near background levels (Fig. 5CGo). Loss of IRS-1 and -2 proteins during forced involution has also been observed in a separate series of studies on developmental regulation of these proteins during a complete lactational cycle (Lee, A.V., and D. L. Hadsell, unpublished observations). These data support the hypothesis that decreased IRS-1 and -2 expression in the epithelium is associated with an inability of overexpressed des (1, 2, 3)hIGF-I to inhibit mammary gland apoptosis during forced involution.



View larger version (144K):
[in this window]
[in a new window]
 
Figure 5. Immunohistochemical detection of IRS-1 protein in mammary tissue sections from mice during mammary involution. Mammary tissue sections from nontransgenic mice undergoing either natural (A and B) or forced (C and D) mammary involution were stained with anti-IRS-1 antibody at a dilution of 1:800. The images were captured at a magnification of x400 and are representative of four mice each. Exclusion of the primary antibody from the staining reactions served as a negative control (B and D). A, The arrows illustrate IRS-negative mammary epithelial cell nuclei that are surrounded by intensely IRS-1-positive cytoplasm.

 
We and others have shown that steroid hormones can increase IRS-1 and IRS-2 mRNA levels (20, 21). We therefore examined whether the change in IRS expression during involution was paralleled by a loss of steroid hormone receptor expression [estrogen receptor (ER) or progesterone receptor (PR)]. We, therefore, immunostained mammary tissue sections from nontransgenic mice on days 8, 16, and 22 postpartum. Nuclear staining of ER and PR was readily detectable in both mammary gland and ovarian tissue from 6-week-old virgin mice. In contrast, ER and PR levels were low or undetectable in mammary gland sections from mice on 8, 16, and 22 days postpartum (data not shown). Furthermore, no change in ER or PR expression was seen in mammary glands on days 8, 16, and 22 postpartum. To determine whether the decreased abundance of IRS proteins was due to decreased mRNA abundance, RPA assays were conducted on pools of RNA prepared from mammary tissue of nontransgenic or WAP-DES mice during either natural or forced involution (Fig. 6Go). The results of this analysis demonstrated that the changes in IRS protein levels during involution occurred independently of ER and PR status, and that the abundance of the IRS-1 and -2 mRNAs was similar between nontransgenic and WAP-DES mice and did not change in response to natural or forced involution.



View larger version (80K):
[in this window]
[in a new window]
 
Figure 6. Abundance of IRS-1 and -2 mRNA during mammary involution. Ribonuclease protection analysis of the IRS-1 and -2 mRNA was conducted in total RNA pools prepared from mammary tissue of either nontransgenic (lanes 1–4 and 9–12) or WAP-DES (lanes 5–8 and 13–16) mice during either natural (lanes 1–8) or forced (lanes 9–16) involution. Each lane contains 40 µg RNA from a pooled RNA sample representing a minimum of four mice. Total RNA prepared from mouse liver served as a positive control (lane 17). Yeast RNA served as a negative control (lane 18). The undigested probe is in lane 19. The expected sizes of the undigested probes are 502, 384, and 168 nt for IRS-1, IRS-2 and cyclophilin, respectively. The expected sizes of the protected fragments are 447, 329, and 103 for IRS-1, IRS-2, and cyclophilin, respectively.

 
Activation of cell survival has, in some models, been demonstrated to occur through an IRS/PI3 kinase-dependent activation of Akt (12, 22, 23). To determine whether activation and/or expression of Akt were related to the ability of IGF-I to protect the mammary gland from apoptosis, both phospho-Akt and total Akt were measured by Western blotting. Phosphorylated Akt was detectable in extracts prepared from mammary tissue obtained during both natural (Fig. 7AGo, lanes 3–11) and forced (Fig. 7AGo, lanes 12–19) involution. The abundance of phospho-Akt was dramatically reduced with forced involution. In addition, there appeared to be moderate enhancement of phospho-Akt in extracts prepared from WAP-DES mice during forced involution compared with that in nontransgenic mice. These results were obtained in two separate sets of gels run with two independently prepared sets of extracts. In both sets of extracts there was no apparent effect of day of involution on the abundance of Akt. Therefore, the densitometric data for day of involution were collapsed within each genotype/involution combination to allow statistical analysis of treatment effects. This analysis demonstrated that the overall abundance of phospho-Akt was decreased (P < 0.05) in forced involution to only 12% of that observed during natural involution (Fig. 7BGo). Overall abundance of total Akt during forced involution was decreased (P < 0.05) to 33% of that observed during natural involution (Fig. 7CGo). The enhancement (P < 0.05) of phospho-Akt in WAP-DES mice during forced involution, although statistically significant, was relatively small compared to the overall reduction that was observed with forced involution. In addition, this small, but statistically significant, increase in phospho-Akt was not accompanied by a similarly significant increase in total Akt. Like IRS-1 and -2, the decrease in Akt preceded the onset of apoptosis during forced involution. Reprobing of the blots demonstrated little effect of genotype or involution on K18 abundance.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
This study demonstrates that overexpression of des(1, 2, 3)IGF-I has a differential capacity to inhibit apoptosis in the involuting mammary gland depending on whether the involution is allowed to occur naturally or is forced. This differential response could be the result of a number of phenomena. These include decreased concentrations, bioavailability or bioactivity of des(1, 2, 3)IGF-I during forced involution, or decreased responsiveness of the mammary epithelium to des(1, 2, 3)IGF-I during force involution.

The direct measurement of des(1, 2, 3)hIGF-I concentrations demonstrate that the tissue concentrations present in the mammary glands of the WAP-DES mice during forced involution are essentially the same as those observed during natural involution, with the exception of elevated concentrations on day 22. Although this elevation on day 22 is counterintuitive and currently unexplained, it also probably has little relevance to the apoptotic processes that began on days 18–20 postpartum. The concentrations of des(1, 2, 3)hIGF-I are much higher than those of endogenous IGF-I and are probably more than adequate to stimulate a responsive epithelium. Because the des(1, 2, 3)IGF-I analog expressed by the WAP-DES transgene has reduced affinity for all IGFBPs (24, 25, 26), reduced bioavailability through interaction with IGFBPs seems unlikely. The present studies cannot, however, rule out the possibility that the differential ability of WAP-DES to inhibit apoptosis is due to decreased bioactivity during forced involution. Despite this caveat, we believe that the data strongly implicate the third possibility, that mammary epithelial cells lose their responsiveness to IGF signals during the early stages of forced involution.

The IRS proteins have been shown to mediate proliferative and antiapoptotic responses in a number of different insulin/IGF-I-responsive cell types and tissues, including breast tumor cells (20, 27, 28). Analyses of the tyrosine phosphorylation state of IGF-IR or signaling molecules such as IRS-1 would presumably serve as a meaningful indicator of IGF-I bioactivity based on cell culture models (29). Although the procedures used in these studies were not sensitive enough to detect phosphorylated IGF-IR in involuting mammary tissue extracts, phosphorylation of IRS-1, IRS-2, and Akt was detectable. The fact that the phosphorylation state of these molecules showed only modest increases in the pooled extracts from WAP-DES mice was probably due to high background phosphorylation in those derived from the nontransgenics. In addition to phosphorylation by insulin or IGF-I receptors, IRS-1 and -2 could serve as substrates for JAK2-dependent phosphorylation in response to PRL or GH stimulation (30). Importantly, the level of tyrosine phosphorylation of IRS-1 declined significantly with the onset of forced involution. This decline was associated not with decreased IGF-IR abundance, but with a decrease in the abundance of IRS-1 protein. The ability to detect IRS-2 phosphorylation during forced, but not natural, involution is somewhat puzzling and remains unexplained. However, like IRS-1, a dramatic loss of IRS-2 protein occurred with the onset of forced involution.

The dramatic decrease in phospho-Akt levels during forced involution correlated with the decline in IRS-1 and -2 phosphorylation and expression and was only partially explained by a decrease in the abundance of Akt protein. This decrease is consistent with previous reports demonstrating IRS dependence of Akt phosphorylation (12, 22, 23). The presence of detectable phospho-Akt in mammary extracts during forced involution in the absence of detectable IRS phosphorylation, however, supports the possibility that other factors can mediate Akt phosphorylation in the absence of IRS proteins. The observation that phospho-Akt was higher in extracts prepared from WAP-DES mice during forced involution suggests that these other factors may be capable of mediating an IGF signal. The integrin-linked kinase has been shown to phosphorylate and activate Akt in an insulin-dependent, PI3 kinase-dependent, fashion (31). These potential IRS-independent mechanisms, however, must serve a relatively minor role, because the most dramatic changes in Akt phosphorylation correlated with the loss of IRS-1. During the course of these studies an attempt was also made to measure the abundance of both BAD and phospo-BAD as a means of determining whether the apoptotic pathway downstream of Akt was also decreased during force involution. These attempts were unsuccessful due to sensitivity limitations of the available antibodies.

The interpretation of the differences between forced and natural involution with respect to IRS-1, IRS-2, and Akt abundance must include two important considerations. Firstly, these decreases occurred during a time when the mammary gland undergoes significant epithelial cell loss. The wet weight data in Fig. 1Go illustrates this loss and agrees with previously published morphometric data that suggest that over the course of 6 days of forced involution the mammary gland loses about half of its epithelial cell population (10). On this basis, the abundance of epithelial markers such as K18 would be expected to change by 2-fold at most. The small changes in K18 abundance after 4 days of involution in the present study agree with previously published results (10), which showed only minimal changes in K18 abundance over 6 days of forced involution. This is probably due to the fact that despite losses over 4–6 days of involution the epithelium remain the predominant contributor on a mass basis to the protein that would be obtained from a whole gland lysate. Hence the loss of epithelium that occurs during forced involution is far too small to account for the 10-fold loss in IRS-1, IRS-2, and phospho-Akt. The second consideration in the comparison of natural with forced involution is the potential for differences to exist in the rate of epithelial cell loss between the two paradigms. Although direct comparisons between forced and natural involution in the mouse are limited (1), studies of lactation in a variety of species support the suggestion that the main difference between the two paradigms is the occurrence of transient alveolar, distension, and diminished secretion of galactopoietic hormones (32). Data from the present study demonstrate that overall mammary gland weight loss during the 4 days of forced involution was similar to that which occurred over 6 days of natural involution. Hence, the daily rate of epithelial loss during natural involution could be estimated to be about 66% of that observed with forced involution. This observation coupled with the finding that K18 abundance showed little systematic change between natural and forced involution support the conclusion that epithelial cell loss does not account for the dramatic differences in the abundance of IRS-1, IRS-2, and phospho-Akt. The immunohistochemical staining for IRS-1 (Fig. 5Go) supports the conclusion that the decreased IRS-1 detected by Western blotting is predominantly due to decreased expression of IRS-1 in the epithelium. This conclusion does not imply that IRS-1 is not expressed in adipocytes of the mammary gland. In fact, immunohistochemical staining suggests that it is expressed in mammary adipocytes (data not shown). However, as greater than 97% of a typical adipocyte consists of either lipid or water, the actual contribution of mammary adipocytes to the total protein present in the whole gland lysates analyzed in these studies is probably small (33). In addition, the increase in adipocyte number or volume during involution is not associated with an increase in IRS-1 expression, suggesting that adipocytes are probably not the predominant cell type responsible for the loss in IRS-1 expression in the present studies.

The observation that IRS-1 and -2 mRNA abundance does not change with forced involution supports the conclusion that these decreases in IRS-1 and -2 are due to changes in protein turnover and that the regulation of IRS proteins in the mammary gland in vivo differs from the steroid hormone-dependent regulation that has been documented in cell culture models (20, 21). Immunohistochemistry conducted on mammary tissue from mice undergoing either natural or forced involution failed to detect the expression of ER{alpha} and PR. This observation is consistent with the findings of previous studies of estrogen and progesterone responsiveness of the mammary gland (34) and supports the suggestion that the steroid-dependent regulation of IRS mRNA abundance in not involved with the loss of IRS during mammary involution. Instead, altered IRS protein turnover analogous to a proteasome-dependent mechanism that has recently been described in several cell types (35, 36) is a more likely mechanism. Investigation of this possibility is currently in progress.

In summary, these studies highlight the existence of mechanistic differences between the regulation of natural and forced mammary gland involution and suggest an important role for key members of the IGF signaling pathway in the maintenance of IGF-I-dependent mammary cell survival. Further studies using animal models with targeted alterations in these signaling molecules will determine the mechanistic importance of IRS expression to mammary gland involution.


    Acknowledgments
 
The authors thank Liz Hopkins for processing the tissue sections, Louise Hadsell for help in enumerating the TUNEL results, Nicholas Sassin for help in the analysis of tissue IGF-I concentrations, Sharon Bonnette for help with the IRS RPA, and Ping Zhang for help with the immunoblots. The authors also thank Dr. D. C. Allred and his staff for performing the immunohistochemistry for IRS-1, ER{alpha}, and PR. Thanks to Drs. Doug Burrin, Jeff Rosen, and Dan Medina for critical review of the manuscript.


    Footnotes
 
1 This work was supported by NIH Grant DK-52197-01 and USDA Cooperative Agreement 58-62550-6-001. This work is a publication of the USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital (Houston, TX). The contents of this publication do not necessarily reflect the views or policies of the USDA, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. Back

2 Recipient of a Susan G. Komen Foundation Research Award. Back

Received September 8, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Quarrie LH, Addey CV, Wilde CJ 1996 Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. J Cell Physiol 168:559–569[CrossRef][Medline]
  2. Marti A, Lazar H, Ritter P, Jaggi R 1999 Transcription factor activities and gene expression during mouse mammary gland involution. J Mammary Gland Biol Neoplasia 4:145–152[CrossRef][Medline]
  3. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z 1996 Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 122:181–193[Abstract]
  4. Schorr K, Li M, Krajewski S, Reed JC, Furth PA 1999 Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 4:153–164[CrossRef][Medline]
  5. Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson E, Marconi S, Naber SP 1998 Delayed involution of the mammary epithelium in BALB/c-p53null mice. Oncogene 17:2305–2312[CrossRef][Medline]
  6. Travers MT, Barber MC, Tonner E, Quarrie L, Wilde CJ, Flint DJ 1996 The role of prolactin and growth hormone in the regulation of casein gene expression and mammary cell survival: relationships to milk synthesis and secretion. Endocrinology 137:1530–1539[Abstract]
  7. Feng Z, Marti A, Jehn B, Altermatt HJ, Chicaiza G, Jaggi R 1995 Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 131:1095–1103[Abstract/Free Full Text]
  8. Tonner E, Quarrie L, Travers M, Barber M, Logan A, Wilde C, Flint D 1995 Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Prog Growth Factor Res 6:409–414[CrossRef][Medline]
  9. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ 1997 Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 138:5101–5107[Abstract/Free Full Text]
  10. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Kiyoshi T, Akira S, Clarke AR, Watson CJ 1999 Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of stat3. Genes Dev 13:2604–2616[Abstract/Free Full Text]
  11. Dews M, Nishimoto I, Baserga R 1997 IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Recept Signal Transduct 7:231–240[Medline]
  12. Yenush L, Zanella C, Uchida T, Bernal D, White MF 1998 The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 18:6784–6794[Abstract/Free Full Text]
  13. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241[CrossRef][Medline]
  14. Neuenschwander S, Schwartz A, Wood TL, Roberts CT, Jr, Hennighausen L, LeRoith D 1996 Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225–2232[Medline]
  15. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM 1996 Targeted expression of des(1–3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137:321–330[Abstract]
  16. Hadsell DL, Murphy KL, Reece N, Alexeenko T, Lascerica R, Rosen JM 2000 Cooperation between des(1–3)IGF-I and mutant p53 accelerates mammary gland carcinogenesis in bigenic mice. Oncogene 19:889–898[CrossRef][Medline]
  17. Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM 1998 A transgenic mouse model for mamary carcinogenesis. Oncogene 16:997–1007[CrossRef][Medline]
  18. Gavrieli Y, Sherman Y, Ben-Sasson SA 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501[Abstract/Free Full Text]
  19. D’Ercole AJ, Stiles AD, Underwood LE 1984 Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81:935–939[Abstract/Free Full Text]
  20. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787–796[Abstract/Free Full Text]
  21. Vassen L, Wegrzyn W, Klein-Hitpass L 1999 Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol Endocrinol 13:485–494[Abstract/Free Full Text]
  22. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME 1997 Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661–664[Abstract/Free Full Text]
  23. Franke TF, Kaplan DR, Cantley LC, Toker A 1997 Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275:665–667[Abstract/Free Full Text]
  24. Clemmons DR, Dehoff MH, Busby WH, Bayne ML, Cascieri MA 1992 Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by IGFs and IGF analogs. Endocrinology 131:890–895[Abstract]
  25. Oh Y, Muller HL, Lee DY, Fielder PJ, Rosenfeld RG 1993 Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1–4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132:1337–1344[Abstract]
  26. Wong MS, Fong CC, Yang M 1999 Biosensor measurment of the interaction kinetics between insulin-like growth factors and their binding proteins. Biochim Biophys Acta 1432:293–301[CrossRef][Medline]
  27. Guvakova MA, Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606–2610[Abstract/Free Full Text]
  28. Ando S, Panno ML, Salerno M, Sisci D, Mauro L, Lanzino M, Surmacz E 1998 Role of IRS-1 in insulin-induced modulation of estrogen receptors in breast cancer cells. Biochem Biophys Res Commun 253:315–319[CrossRef][Medline]
  29. Myers MGJ, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, White MF 1993 IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3' kinase. Endocrinology 132:1421–1430[Abstract]
  30. Yamauchi T, Kaburagi Y, Ueki K, Tsuji Y, Stark GR, Kerr IM, Tsushima T, Akanuma Y, Komuro I, Tobe K, Yazaki Y, Kadowaki T 1998 Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. J Biol Chem 273:15719–15726[Abstract/Free Full Text]
  31. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S 1998 Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95:11211–11216[Abstract/Free Full Text]
  32. Wilde CJ, Knight CH, Flint DJ 1999 Control of milk secretion and apoptosis during mammary involution. J Mammary Gland Biol Neoplasia 4:129–136[CrossRef][Medline]
  33. DiGirolamo M, Owens JL 1976 Water content of rat adipose tissue and isolated adipocytes in relation to cell size. Am J Physiol 231:1568–1572[Abstract/Free Full Text]
  34. Shyamala G, Schneider W, and Schott D 1990 Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology 126:2882–2889[Abstract]
  35. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ 1999 Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteosomal degradaiont pathway. Diabetes 48:1359–1364[Abstract]
  36. Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D 2000 Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26s proteosome and blocked by phosphatidylinositol 3'-kinase inhibition. Mol Cell Biol 20:1489–1496[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J EndocrinolHome page
D. L Hadsell, A. F Parlow, D. Torres, J. George, and W. Olea
Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression
J. Endocrinol., July 1, 2008; 198(1): 61 - 70.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
D. L Hadsell, W. Olea, N. Lawrence, J. George, D. Torres, T. Kadowaki, and A. V Lee
Decreased lactation capacity and altered milk composition in insulin receptor substrate null mice is associated with decreased maternal body mass and reduced insulin-dependent phosphorylation of mammary Akt
J. Endocrinol., August 1, 2007; 194(2): 327 - 336.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. M. McDaniel, K. K. Rumer, S. L. Biroc, R. P. Metz, M. Singh, W. Porter, and P. Schedin
Remodeling of the Mammary Microenvironment after Lactation Promotes Breast Tumor Cell Metastasis
Am. J. Pathol., February 1, 2006; 168(2): 608 - 620.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
D. L. Hadsell, D. T. Torres, N. A. Lawrence, J. George, A. F. Parlow, A. V. Lee, and M. L. Fiorotto
Overexpression of Des(1-3) Insulin-Like Growth Factor 1 in the Mammary Glands of Transgenic Mice Delays the Loss of Milk Production with Prolonged Lactation
Biol Reprod, December 1, 2005; 73(6): 1116 - 1125.
[Abstract] [Full Text] [PDF]


Home page
J DAIRY SCIHome page
E. L. Annen, R. J. Collier, M. A. McGuire, and J. L. Vicini
Effects of Dry Period Length on Milk Yield and Mammary Epithelial Cells
J Dairy Sci, July 1, 2004; 87(13_suppl): E66 - 76.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. A. Green, M. J. Naylor, E. T. Lowe, P. Wang, E. Marshman, and C. H. Streuli
Caspase-mediated Cleavage of Insulin Receptor Substrate
J. Biol. Chem., June 11, 2004; 279(24): 25149 - 25156.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. A. Allar and T. L. Wood
Expression of the Insulin-Like Growth Factor Binding Proteins during Postnatal Development of the Murine Mammary Gland
Endocrinology, May 1, 2004; 145(5): 2467 - 2477.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. L. Hadsell, S. Bonnette, J. George, D. Torres, Y. Klementidis, S. Gao, P. M. Haney, J. Summy-Long, M. S. Soloff, A. F. Parlow, et al.
Diminished Milk Synthesis in Upstream Stimulatory Factor 2 Null Mice Is Associated With Decreased Circulating Oxytocin and Decreased Mammary Gland Expression of Eukaryotic Initiation Factors 4E and 4G
Mol. Endocrinol., November 1, 2003; 17(11): 2251 - 2267.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. V. Lee, P. Zhang, M. Ivanova, S. Bonnette, S. Oesterreich, J. M. Rosen, S. Grimm, R. C. Hovey, B. K. Vonderhaar, C. R. Kahn, et al.
Developmental and Hormonal Signals Dramatically Alter the Localization and Abundance of Insulin Receptor Substrate Proteins in the Mammary Gland
Endocrinology, June 1, 2003; 144(6): 2683 - 2694.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell
New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation
Clin. Cancer Res., January 1, 2003; 9(1): 516S - 523S.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. L. Grimm, T. N. Seagroves, E. B. Kabotyanski, R. C. Hovey, B. K. Vonderhaar, J. P. Lydon, K. Miyoshi, L. Hennighausen, C. J. Ormandy, A. V. Lee, et al.
Disruption of Steroid and Prolactin Receptor Patterning in the Mammary Gland Correlates with a Block in Lobuloalveolar Development
Mol. Endocrinol., December 1, 2002; 16(12): 2675 - 2691.
[Abstract] [Full Text] [PDF]


Home page
Endocrinology